Stage III Squamous Cell Carcinoma of the Lip and Oral Cavity Completed Phase 2 Trials for Erlotinib (DB00530)

IndicationStatusPhase
DBCOND0028768 (Stage III Squamous Cell Carcinoma of the Lip and Oral Cavity)Completed2
clinicaltrials.gov IdentifierTitlePurposeDrugs
NCT00410826Cisplatin and Radiation Therapy With or Without Erlotinib Hydrochloride in Treating Patients With Stage III or Stage IV Head and Neck CancerTreatment